on TME PHARMA N.V. (isin : NL0015000YE1)
TME Pharma Outlines 2025 Strategic Roadmap and Initiatives
TME Pharma N.V., a biotechnology company focused on cancer therapies, has released a message from CEO Aram Mangasarian detailing the company's strategic roadmap for 2025. Key initiatives include strategic partnerships, advancing the NOX-A12 clinical program, and leveraging AI in drug discovery. The company is actively engaging with potential partners and investors to enhance shareholder value.
Preparations for the Phase 2 trial of NOX-A12 in glioblastoma are progressing, backed by over €7 million in funding, including a €2.4 million German grant. The company also emphasizes its strengthened financial position following a successful public offer of €2.6 million in December 2024.
Additionally, TME Pharma explores the potential of NOX-E36 in ophthalmology. Despite challenges, they remain optimistic about NOX-A12's therapeutic potential in glioblastoma, seeking strategic partnerships to further its development.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TME PHARMA N.V. news